Drug Trial Radar · NCT05455320
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
864
Actual
Start
Oct 13, 2022
Primary completion
Jul 30, 2027
Study completion May 25, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Conditions
- Multiple Myeloma
Interventions
TalquetamabDrug
Talquetamab will be administered subcutaneously.
DaratumumabDrug
Daratumumab will be administered subcutaneously.
PomalidomideDrug
Pomalidomide will be administered orally.
DexamethasoneDrug
Dexamethasone will be administered orally or intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to 6 years 6 months
Locations
216 sites in 18 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Norwalk Hospital-oncology
Norwalk, Connecticut
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
George Washington University
Washington D.C., District of Columbia
Memorial Healthcare System
Hollywood, Florida
University of Miami Health System
Miami, Florida
University Of Illinois
Chicago, Illinois
University of Kansas
Westwood, Kansas
Tulane University Hospital & Clinics
New Orleans, Louisiana
Ochsner Health System
New Orleans, Louisiana
Johns Hopkins University
Baltimore, Maryland
Massachusetts General
Boston, Massachusetts
Boston University Medical Center
Boston, Massachusetts
University of Massachusetts Medical School
Worcester, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
University Of Minnesota
Minneapolis, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
Washington University School Of Medicine
St Louis, Missouri
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
NYU Langone Health
New York, New York
SUNY Upstate Medical University
Syracuse, New York
University of North Carolina
Chapel Hill, North Carolina
Levine Cancer Institute, Carolinas HealthCare System
Charlotte, North Carolina
Novant Health 1
Charlotte, North Carolina
Novant Health
Winston-Salem, North Carolina
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Ohio State University Wexner Medical Center - James Cancer Hospital
Columbus, Ohio
OhioHealth
Columbus, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Baptist Cancer Center
Memphis, Tennessee
Houston Methodist Hospital
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
Joe Arrington Cancer Research Treatment Center
Lubbock, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
University of Virginia
Charlottesville, Virginia
Virginia Commonwealth University - Massey Cancer Center
Richmond, Virginia
Fred Hutchinson Cancer Research Center
Seattle, Washington
Showing 40 of 216 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.